This article was originally published in The Gray Sheet
Minneapolis-based urology firm lays off 26% of its workforce (28 employees), hires Fred Parks as CEO and chairman of the board upon CEO Michael Selzer's resignation. Parks has served as CEO of Marconi Medical Systems and Philips Medical Systems-Cleveland, and held the COO title at St. Jude Medical (1"The Gray Sheet" March 8, 1999, p. 23). Urologix will take a restructuring charge in the fourth quarter...
You may also be interested in...
Topside personnel changes at St. Jude Medical are unlikely to have a short-term impact on the company's strategic plan, incoming President and CEO Terry Shepard commented during a March 2 teleconference announcing the management changes at the St. Paul, Minnesota device manufacturer.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.